miR-483-3p plays an oncogenic role in esophageal squamous cell carcinoma by targeting tumor suppressor EI24
- PMID: 26801660
- DOI: 10.1002/cbin.10585
miR-483-3p plays an oncogenic role in esophageal squamous cell carcinoma by targeting tumor suppressor EI24
Abstract
microRNAs (miRNAs), through negatively regulating their target genes, influence the development and progression of many cancers. Previously, we found miR-483 was overexpressed in esophageal squamous cell carcinoma (ESCC) tissues, and its overexpression was negatively correlated with the prognosis and positively correlated with multidrug resistance of ESCC, but whether it could affect the biological role of proliferation and migration in ESCC cell lines is unknown. In the present study, we found miR-483-3p was overexpressed in ESCC cell lines as compared with the normal esophageal squamous epithelial cell line. Functional experiments in vitro showed that miR-483-3p could promote the proliferation, migration, transformation of cell cycle from G1 phase to G2 phase of ESCC cells and could inhibit cells' sensitivity to chemotherapy drugs. Nude mouse tumorigenicity assay indicated that miR-483-3p could promote the growth of ESCC cells in vivo. Western blot assay showed that ectopic expression of miR-483-3p in ESCC cells could downregulate the protein level of etoposide induced 2.4 (EI24), which is a tumor suppressor and has not been reported in ESCC. Luciferase reporter assay demonstrated that EI24 was a direct target of miR-483-3p. Collectively, our study demonstrated that miR-483-3p could promote ESCC progression at least in part through directly targeting EI24, supplying a potential strategy for miRNA-based ESCC therapy.
Keywords: EI24; drug resistance; esophageal squamous cell carcinoma; miR-483-3p; migration; proliferation.
© 2016 International Federation for Cell Biology.
Similar articles
-
MiR-455-3p acts as a prognostic marker and inhibits the proliferation and invasion of esophageal squamous cell carcinoma by targeting FAM83F.Eur Rev Med Pharmacol Sci. 2017 Jul;21(14):3200-3206. Eur Rev Med Pharmacol Sci. 2017. PMID: 28770965
-
Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.J Exp Clin Cancer Res. 2017 Nov 16;36(1):161. doi: 10.1186/s13046-017-0622-1. J Exp Clin Cancer Res. 2017. PMID: 29145896 Free PMC article.
-
miR-516b functions as a tumor suppressor by directly modulating CCNG1 expression in esophageal squamous cell carcinoma.Biomed Pharmacother. 2018 Oct;106:1650-1660. doi: 10.1016/j.biopha.2018.07.074. Epub 2018 Jul 29. Biomed Pharmacother. 2018. PMID: 30119241
-
[The role of microRNA-210 in esophageal squamous cell carcinoma].Yakugaku Zasshi. 2012;132(9):1069-73. doi: 10.1248/yakushi.132.1069. Yakugaku Zasshi. 2012. PMID: 23023426 Review. Japanese.
-
The role of microRNA in esophageal squamous cell carcinoma.J Gastroenterol. 2016 Jun;51(6):520-30. doi: 10.1007/s00535-016-1161-9. Epub 2016 Jan 21. J Gastroenterol. 2016. PMID: 26794004 Review.
Cited by
-
Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.Oncotarget. 2016 Sep 20;7(38):62034-62048. doi: 10.18632/oncotarget.11500. Oncotarget. 2016. PMID: 27566562 Free PMC article.
-
Identification of genes associated with histologic tumor grade of esophageal squamous cell carcinoma.FEBS Open Bio. 2017 Jul 28;7(9):1246-1257. doi: 10.1002/2211-5463.12228. eCollection 2017 Sep. FEBS Open Bio. 2017. PMID: 28904855 Free PMC article.
-
EI24 Inhibits Cell Proliferation and Drug Resistance of Esophageal Squamous Cell Carcinoma.Front Oncol. 2020 Aug 21;10:1570. doi: 10.3389/fonc.2020.01570. eCollection 2020. Front Oncol. 2020. PMID: 32974192 Free PMC article.
-
eNOS expression and NO release during hypoxia is inhibited by miR-200b in human endothelial cells.Angiogenesis. 2018 Nov;21(4):711-724. doi: 10.1007/s10456-018-9620-y. Epub 2018 May 8. Angiogenesis. 2018. PMID: 29737439 Free PMC article.
-
The Prospective Application of Melatonin in Treating Epigenetic Dysfunctional Diseases.Front Pharmacol. 2022 May 20;13:867500. doi: 10.3389/fphar.2022.867500. eCollection 2022. Front Pharmacol. 2022. PMID: 35668933 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources